Premium
Retained role of surgery for olfactory neuroblastoma
Author(s) -
Smee Robert I.,
Broadley Kathryn,
Williams Janet R.,
Meagher Nicola S.,
Bridger G. Patrick
Publication year - 2011
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21644
Subject(s) - medicine , esthesioneuroblastoma , radiation therapy , etoposide , surgery , stage (stratigraphy) , chemotherapy , neuroblastoma , malignancy , paleontology , biology , genetics , cell culture
Background Olfactory neuroblastoma is a rare paranasal sinus malignancy. The traditional approach was craniofacial resection (CFR) and then postoperative radiotherapy until 1998. This review will chart development of a new protocol. Methods This ethics‐approved audit evaluated the number of new patients diagnosed with olfactory neuroblastoma, with information relating to patient, disease, and treatment factors noted. Results There were 24 eligible patients, 16 men, 8 women, 7 Kadish stage B, 17 stage C. The planned treatment was: chemotherapy (cisplatin/etoposide) and determine treatment dependent on response in 6 patients, surgery and radiotherapy in 16 patients, and single‐modality treatment only (surgery, radiotherapy 1) in 2 patients. Surgery to radiotherapy occurred in 17 patients. With salvage treatment ultimate local control was 79%. Conclusions There was a higher local control in those patients who had surgery; abandoning this may carry a higher risk of local failure. The use of response to chemotherapy to determine local treatment remains experimental. © 2010 Wiley Periodicals, Inc. Head Neck, 2010